Drs. Kuykendall and Hobbs on MPN care in 2025
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Drs. Kuykendall and Hobbs on MPN care in 2025
-
ナレーター：
-
著者：
このコンテンツについて
Andrew Kuykendall, MD, of Moffitt Cancer Center in Tampa, Florida hosts a podcast on the latest news in myeloproliferative neoplasms (MPNs) with guest Gabriela Hobbs, MD, of Massachusetts General Research Institute.
The pair discuss treatment goals for patients with MPNs, especially as treatments evolve and become more targeted.
“As therapies get better, we can offer more to our patients,” Dr. Hobbs said.
One upcoming abstract of interest at ASCO® 2025 includes Dr. Kuykendall’s oral abstract, titled “Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV),” which will be available for attendees on June 1, 2025, the ASCO® 2025 website.
They also discussed patients’ heart risks and pulmonary hypertension, needing teamwork with other doctors.
“We really need to strengthen those relationships with other specialties,” Dr. Kuykendall said.
Listen to more podcasts on SOHO Insider.